melphalan and methylformamide

Leukemic cells have been shown to generate several classes of DNA fragments after treatment with cytotoxic cancer chemotherapy agents. However, it is unclear which of these fragmentation events are a direct effect of DNA-damaging chemotherapy agents, and which fragmentation events are caused by downstream processes, such as apoptosis. We have performed a detailed analysis of DNA fragmentation events which occur following cytotoxic chemotherapy in four representative leukemic cell lines (HL-60, Jurkat, K562, and Molt-4). We used a DNA topoisomerase II inhibitor (etoposide), an alkylating agent (melphalan), a nucleoside analog (cytosine arabinoside), and a non-genotoxic agent (N-methylformamide) to induce cell death. We studied high molecular weight and low molecular weight DNA fragmentation events, as well as the specific cleavage of the MLL breakpoint cluster region (bcr). The DNA fragments produced at late time points were largely independent of the agents used, while those generated at earlier time points showed clear differences in terms of fragment size and relative abundance, depending on the agent used. In addition, there were clear differences between cell lines in terms of size, relative abundance, and rate at which DNA fragments were produced by treatment with the same agents. We think that this survey documents the importance of studying several different cell lines, time points, and assays before reaching conclusions about the types of DNA fragments produced during treatment with cytotoxic agents, and provides a useful framework for studying a wide range of DNA fragments produced by cytotoxic agents.

Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cytarabine; DNA; DNA Damage; DNA Fragmentation; Electrophoresis, Gel, Pulsed-Field; Enzyme Inhibitors; Etoposide; Formamides; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Melphalan; Topoisomerase II Inhibitors; Tumor Cells, Cultured

The effects of the differentiation-inducing polar solvent N-methylformamide (NMF) on the in vitro response of murine hepatocarcinoma (HCa-1) cells to 1,3-bis(2-chloroethyl)-1-nitrosourea, cis-diamminedichloroplatinum (II), and melphalan were investigated using the sister chromatid exchange (SCE) and cell survival assays. When cells were exposed to 1.25% NMF, cell culture doubling time increased from 12 to 43 h and cell volume increased from 940 microns 3 to 1440 microns 3. Growth of HCa-1 cells in NMF for 96 h before drug treatment enhanced the SCEs induced by each of the three chemotherapeutic agents. For each drug, maximum enhancement occurred after 72 h of NMF pretreatment, and the enhancement was eliminated 48 h after NMF was removed. Pretreatment with 1.25% NMF for 96 h also enhanced the cell kill induced by each drug. NMF exposure modified primarily the low-dose shoulder region of each drug cell survival curve. The data indicate that NMF is an effective chemosensitizing agent for HCa-1 cells in vitro and suggest that NMF may provide clinical benefits when administered in combination with antineoplastic drugs.

Topics: Animals; Antineoplastic Agents; Carmustine; Cell Differentiation; Cell Survival; Cisplatin; Drug Synergism; Formamides; Humans; Liver Neoplasms, Experimental; Melphalan; Mice; Sister Chromatid Exchange; Tumor Stem Cell Assay